PharmaCyte Biotech Proposes Reverse Stock Split to Avoid Delisting, Seeks Approval for Significant Equity Dilution

summarizeSummary

PharmaCyte Biotech is proposing a reverse stock split to avoid Nasdaq delisting and seeking approval to add 2,000,000 shares to its equity incentive plan, signaling significant potential dilution and ongoing challenges.

check_boxKey Events

• Reverse Stock Split Proposed to Avoid Delisting

  The Board unanimously approved, subject to shareholder approval, a reverse stock split with a ratio between 1-for-1.1 and 1-for-100. This action is primarily aimed at increasing the per-share trading price to meet Nasdaq's minimum bid price requirement and avoid delisting.

• Nasdaq Delisting Notice Received

  PharmaCyte Biotech received a written notice from Nasdaq on December 1, 2025, indicating non-compliance with the $1.00 minimum bid price rule. The company has a grace period until June 1, 2026, to regain compliance.

• Significant Increase in Equity Incentive Plan Shares

  Shareholders will vote on an amendment to increase the number of shares available for the 2022 Equity Incentive Plan by 2,000,000 shares. This represents a potential dilution of approximately 18.6% of current outstanding common stock if all shares are issued.

• Board Recommends Approval of All Proposals

  The Board of Directors recommends that stockholders vote 'FOR' the election of directors, ratification of auditors, advisory vote on executive compensation, the reverse stock split, and the equity incentive plan amendment.

auto_awesomeAnalysis

PharmaCyte Biotech is seeking shareholder approval for a reverse stock split, with a ratio ranging from 1-for-1.1 to 1-for-100, primarily to regain compliance with Nasdaq's minimum $1.00 bid price requirement. The company received a delisting notice on December 1, 2025, and has until June 1, 2026, to cure the deficiency. A reverse stock split is often viewed negatively by investors as it can signal underlying financial distress and does not change the company's intrinsic value, though it is necessary here to maintain listing. Additionally, the company proposes to increase the number of shares available for its 2022 Equity Incentive Plan by 2,000,000 shares. This represents a potential dilution of approximately 18.6% relative to the current outstanding common stock, which is substantial for a company of this size. This filing follows a significant open market purchase by the CEO on January 7, 2026, which may have been an attempt to support the stock price in light of the delisting threat, but ultimately proved insufficient, leading to these more drastic proposals.